Fenugreek

01 What this document is, and four things it is not

This document is a research review of Trigonella foenum-graecum L. seed: what the seed contains, how commercial products split that chemistry, which human endpoints have been measured, and which safety facts survive a title-checked record. It is written against a single research question. When fenugreek is separated into whole-seed powder, viscous fiber, isolated 4-hydroxyisoleucine, and proprietary saponin extracts, which human claims remain supported, and which are product-class errors?

It is not a treatment guide. No sentence here is an instruction to take fenugreek, to stop a drug, to lactate, to raise testosterone, or to manage glucose. Reported grams and milligrams are study parameters attached to named populations. They are not a schedule.

It is not a warrant that the kitchen spice and the capsule are the same object. Sharma et al., 1990 used 100 g/day of defatted seed powder in insulin-treated type 1 diabetes for ten days. Steels et al., 2011 and Rao et al., 2016 used 600 mg/day of Testofen, a specialized seed extract, in healthy men. Those two exposures do not license each other. Section 11 treats the generalization as an error, not as a rounding problem.

It is not a completed drug article for 4-hydroxyisoleucine. The Montpellier islet and animal series (Sauvaire et al., 1998; Broca et al., 1999, 2000, 2004) maps a glucose-dependent insulinotropic amino acid. Chevassus et al., 2009 and 2010 tested a hydro-alcoholic seed extract on fat intake, not the isolate. Converting those papers into a human 4-hydroxyisoleucine trial is speculative.

It is not a proof that fenugreek is a reliable galactagogue. Foong et al., 2020, in the Cochrane review of oral galactagogues, judged the natural-product evidence at very low certainty and could not meta-analyse fenugreek milk volume or infant weight. A tea trial, a mixed-herb capsule, and a short preterm-volume signal do not lift that ceiling. Reeder and colleagues (Clinical Lactation, 2013) are widely cited in secondary lactation writing; that paper is not PubMed-indexed and is not given a PMID here.

02 Botanical identity

Fenugreek is a member of the Fabaceae. The accepted binomial is Trigonella foenum-graecum L. English names include fenugreek and, in culinary use, methi. The organ under review is the ripe seed. Leaves, sprouts, and “fenugreek tea” bags that do not declare a seed fraction are not this seed, and a tea that merely contains fenugreek among other herbs is not a seed-powder trial (Turkyilmaz et al., 2011). Other Trigonella species are not substitutes. This article is confined to T. foenum-graecum.

The seed is a typical papilionoid grain in construction if not in fame: a hard testa, an endosperm rich in galactomannan gum, and cotyledons that hold protein and the bulk of the steroid saponins. That anatomy is not decorative. Ribes et al., 1986 split the seed and showed that the glycemic work in diabetic dogs travelled with the testa–endosperm fiber fraction, not with the saponin-and-protein cotyledon fraction. Valette et al., 1984 had already shown that a lipid extract was inert on cholesterol in dogs while a defatted fiber-and-saponin remainder was not. The seed is a mixture with addressable rooms. Treating it as a single “active” is a category mistake.

As a food, the seed is a spice, a bittering agent, and a traditional galactagogue and glycemic adjunct in several culinary and Ayurvedic registers. Those histories explain why the trials exist. They do not grade the trials. Culinary incorporation — bread, chapati — is a formulation, not an evidence class of its own, though it can improve blinding when the flavor is masked (Losso et al., 2009). Traditional use is recorded here as context. It is not used as a surrogate for a controlled endpoint.

03 The seed as a mixture

The composition figures that circulate in reviews are review-level, not a new assay. Roberts, 2011 restates seed dietary fiber near 45%, with a minority soluble and the rest insoluble, and notes that fenugreek gum is galactose plus mannose. The LactMed fenugreek chapter inventories mucilage, quercetin, luteolin, genistein, vitexin, trigonelline, 4-hydroxyisoleucine, sotolon, diosgenin, protodioscin, saponins, and isoflavones. Those lists are useful as a map. They are not a certificate that every listed molecule explains a human outcome.

Three mechanical facts organize the rest of the article. First, viscosity and fecal steroid handling can move glucose and cholesterol without any unique fenugreek alkaloid being absorbed. Second, the saponin fraction can be hydrolyzed in the gut to sapogenins, including diosgenin (Sauvaire et al., 1991), and can be concentrated into branded extracts that no longer behave like flour. Third, 4-hydroxyisoleucine is insulinotropic in islets at high micromolar concentrations and glucose-dependently (Sauvaire et al., 1998). That is established chemistry. It is not, on the present file, a human isolate trial. Fuller and Stephens, 2015, reviewing diosgenin, 4-hydroxyisoleucine, and fiber together, already refused a definitive therapeutic role. That refusal still holds.

The practical consequence is that every results sentence in Parts Three and Five names the form. A soaked-seed powder, a 5% fenugreek bread, a hydro-alcoholic extract, a total-saponin tablet, and a protodioscin-standardized capsule are five products. Pooling them under “fenugreek” is how meta-analyses acquire both their signal and their I².

04 Galactomannan

Fenugreek gum is a galactomannan with a high galactose:mannose ratio, near 1:1, more highly substituted than guar (near 1:2) or locust bean (near 1:4). Evans et al., 1992 compared the three gums in cholesterol-challenged rats at 80 g/kg diet. All three lowered plasma and liver cholesterol relative to cellulose or a fiber-free baseline. The highest viscosity was not the most cholesterol-lowering, and fenugreek gum had no direct effect on cholesterol absorption in a perfused intestine. Structure–function, not a human dose, is what that paper established. The point that survives is that viscosity and fermentation, not a unique sugar, are the leading mechanistic account of acute post-prandial glucose blunting and part of the cholesterol effect. That account is strongly supported as mechanism. It is not a claim that fenugreek gum is superior to other viscous fibers in people.

Srichamroen et al., 2009 took galactomannan from Canadian fenugreek seed into everted jejunal and ileal segments from lean and obese rats. At 0.1–0.5% weight/weight, the gum progressively inhibited uptake of 2 and 32 mmol/L glucose. The inhibition paralleled viscosity at 37 °C. Lean and obese segments did not differ. This is an ex vivo transport finding. It is not a clinical exposure. It does, however, make the later human fiber breakfast of Mathern et al., 2009 chemically unsurprising: isolated fenugreek fiber can change satiety and insulin appearance without proving a unique phytochemical.

Ribes et al., 1986 remains the load-bearing fractionation. In alloxan-diabetic dogs already on insulin, a 21-day add-on of subfraction a (testa plus endosperm, 79.6% fiber, viscosity 115 cP) lowered hyperglycemia, glycosuria, glucagon, somatostatin, and the oral-glucose excursion. Subfraction b (cotyledons and axes, 7.2% saponins, 52.8% protein) had no glycemic effect. The authors could not exclude unknown actives travelling with the testa and endosperm. They did exclude the simple story that “the saponins are the antidiabetic principle.” Valette et al., 1984 had shown the same directional split: lipid extract inert; defatted fraction (53.9% fiber, 4.8% steroid saponins) active on cholesterol and, in diabetic dogs, on hyperglycemia. The fiber fraction is the glycemic piece in this classical animal file. Saponins travel, in those same papers, with lipids and, later, with appetite in the opposite direction from fiber (Petit et al., 1995).

05 Saponins and diosgenin

Fenugreek steroid saponins are chiefly furostanol glycosides. In the gut they are hydrolyzed to sapogenins. Sauvaire et al., 1991, using alloxan-diabetic dogs and fecal gas chromatography–mass spectrometry, recovered about 57% of administered saponins as sapogenins — diosgenin, smilagenin, gitogenin — and implicated saponins with or without diosgenin in the hypocholesterolemic effect. That is an animal, fecal-metabolite finding. It is established as chemistry. It is not a quantified human dose–response.

Petit et al., 1995 purified steroid saponins to at least 90% furostanol material and fed 12.5 mg/day per 300 g body weight to normal and streptozotocin-diabetic rats. Food intake and eating motivation rose in normal animals. Diabetic animals stabilized intake and gained weight. Total cholesterol fell. Triglycerides did not. The direction of the appetite effect is the opposite of the later human fiber and extract intake papers (Mathern et al., 2009; Chevassus et al., 2009, 2010). The article keeps that contradiction. “Fenugreek reduces appetite” is not a constituent-free sentence. Purified saponins in rats are not isolated fiber in obese adults, and neither is a 10 g soaked-seed powder.

Diosgenin is the sapogenin that later mechanism papers treat as a named actor. Uemura et al., 2010 fed KK-Ay mice a high-fat diet containing 2% fenugreek, identified diosgenin as an active aglycone, and reproduced adipocyte-differentiation and anti-inflammatory effects in 3T3-L1 cells. A 2% dietary load in a mouse is not a human supplement exposure. The finding is plausible mechanistic support for an adipose-inflammatory pathway. It is not a human outcome. Fuller and Stephens, 2015, placing diosgenin beside 4-hydroxyisoleucine and fiber, again refused a definitive therapeutic role. Industry extracts that standardize on furostanolic saponins or protodioscin (Fenfuro, Furosap, Furocyst) are concentrating this fraction. They are not reconstituting the seed.

06 4-Hydroxyisoleucine

4-Hydroxyisoleucine is an unusual branched-chain amino acid concentrated in fenugreek seed. Haefelé et al., 1997 characterized a seed dioxygenase on the biosynthetic route. The canonical pharmacology is the Montpellier series. Sauvaire et al., 1998, in isolated rat and human islets and in the perfused rat pancreas, showed that purified 4-hydroxyisoleucine stimulates glucose-induced insulin release at 100 µmol/L to 1 mmol/L. The effect is strictly glucose-dependent: inert at 3 or 5 mmol/L glucose, potentiating at 6.6–16.7 mmol/L. Secretion is biphasic. Alpha and delta cells do not change. There is no interaction with leucine, arginine, tolbutamide, or glyceraldehyde. That pattern is established in the preparation. The concentrations are high. The paper is not an in-vivo human study.

Broca et al., 1999 moved the amino acid into animals. 18 mg/kg improved glucose tolerance in normal rats and dogs. The lactone form was ineffective. In neonatally streptozotocin-treated “NIDD” rats, a single 50 mg/kg intravenous dose restored the insulin response without improving glucose tolerance; six days at 50 mg/kg reduced basal hyperglycemia and insulinemia and slightly improved tolerance. Broca et al., 2000 then showed that only the linear major isomer (2S,3R,4S) at 200 µmol/L potentiates insulin at 8.3 mmol/L glucose. Analogues require higher concentrations. The structure–activity rule is α-S configuration, full methylation, and γ-hydroxylation. Broca et al., 2004, now using the industry-style code ID-1101, reported increased peripheral glucose utilization in sucrose-lipid rats, decreased hepatic glucose production in Zucker fa/fa rats, acute PI3K activation in liver and muscle, and a chronic reduction in insulinemia. These are animal clamp and signaling findings. They are the best preclinical map this seed has. They remain preclinical.

Secondary reviews have been willing to get ahead of that map, restating insulinotropic and insulin-signaling claims as if a metabolic-syndrome drug were in hand. This review searched PubMed for 4-hydroxyisoleucine and human, volunteer, or clinical terms and did not recover a title-verified randomized trial of the isolated amino acid. Chevassus et al., 2009 and 2010 used a hydro-alcoholic seed extract. They are not isolate trials. The human-drug claim for 4-hydroxyisoleucine is speculative. The islet pharmacology is established. The gap between those two sentences is the gap this article refuses to paper over.

07 Trigonelline, flavonoids, sotolon

Trigonelline is the major fenugreek alkaloid and is also abundant in coffee. Zhou et al., 2012 reviewed hypoglycemic, hypolipidemic, and neuroprotective activities and listed proposed mechanisms — beta-cell regeneration, insulin secretion, metabolic enzymes, reactive oxygen species — while noting that clinical mechanism remains incomplete. Much of the diabetic trigonelline literature is coffee literature, not fenugreek-seed literature. Treating trigonelline as the hidden active in every seed-powder trial is plausible chemistry and an uncontrolled attribution. This article does not award the seed’s human glycemic signal to trigonelline alone.

Seed-specific flavonoid trials of adequate design are scarce. LactMed lists quercetin, luteolin, genistein, and vitexin among constituents. That is an inventory, not an endpoint paper. Generic naringenin or “phytoextract cream” papers that mention fenugreek in passing are not used here. A flavonoid explanation of the human file is speculative.

Sotolon — sotolone; 4,5-dimethyl-3-hydroxy-2(5H)-furanone — is the impact odorant of fenugreek and the shared odorant of maple syrup and of maple syrup urine disease. Podebrad et al., 1999 identified sotolon in all seven MSUD urines tested and in none of the healthy controls, and noted that the same molecule is the fenugreek odorant. Bartley et al., 1981 had already reported maple-syrup urine odor after fenugreek ingestion. Sewell et al., 1999 described false MSUD suspicion after herbal-tea ingestion. Korman et al., 2001 described neonates with maple-syrup odor after maternal prenatal or intrapartum fenugreek, and stated the chemical link. Girardon et al., 1985 had provided an early volatile profile from the Sauvaire group. The odor is established chemistry. It is also a trial-methods fact: a double-blind seed-powder study that does not mask sotolon is structurally weak. Section 21 returns to that point as safety and as bias.

08 Whole-seed powder versus extracts

The word “fenugreek” in a methods line can mean a soaked household seed, a defatted flour at food scale, a gum isolated from the endosperm, a hydro-alcoholic extract of the whole seed, a total-saponin tablet from a Chinese add-on trial, or a branded concentrate standardized to Fenuside glycosides, protodioscin, or “furostanolic saponins.” Those objects share a plant. They do not share a composition, a milligram scale, a blinding problem, or a commercial incentive. This part names them before Part Three reports endpoints, so that a later sentence cannot quietly change product mid-claim.

Whole-seed powder is the traditional experimental material. The amounts that appear as study parameters run from a 15 g soaked-seed meal test in non-insulin-dependent diabetes (Madar et al., 1988) through 10 g/day powders (Kassaian et al., 2009; Rafraf et al., 2014; Gaddam et al., 2015; Ranade and Mudgalkar, 2017) and 15 g/day (Hadi et al., 2020) to 25 g seed-powder solution twice daily versus metformin (Geberemeskel et al., 2019) and, at the extreme, 100 g/day defatted powder in type 1 diabetes (Sharma et al., 1990). Those are food-level exposures. They taste and smell of fenugreek. Sotolon makes a matching placebo difficult. Academic groups predominate. Industry branding is usually absent. The cost of that honesty is that odor and bitterness are themselves interventions: they unblind, they change palatability, and they can change how much of a meal is eaten for reasons that have nothing to do with an islet amino acid.

Preparation is not a footnote. Kassaian et al., 2009 gave 10 g/day powdered seed either soaked in hot water or mixed into yoghurt for eight weeks in type 2 diabetes. The hot-water arm showed a 25% fall in fasting glucose and a 30% fall in triglycerides among completers. The yoghurt arm did not. Eighteen of 24 enrolled subjects were analysed. There was no placebo. The paper is small and open. It is still a warning: the same labelled grams, in a different vehicle, stopped being a result. Ranade and Mudgalkar, 2017 soaked 10 g seeds in hot water daily for six months in a single-blind parallel trial; fasting glucose reached a between-group p value only at month 5, HbA1c at month 6. The authors called the effect delayed. A no-placebo Ayurveda-journal trial with late isolated p values is not a confirmation of Kassaian. It is another reminder that soaking, vehicle, and time are part of the intervention.

Culinary incorporation can hide the seed. Losso et al., 2009 baked 5% fenugreek into bread and compared two 56 g slices against whole-wheat bread in eight diet-controlled diabetic subjects, double-blind, with meal tests a week apart. Insulin area-under-curve fell. Glucose area-under-curve fell but not significantly. Sensory scores did not distinguish the breads. That is an acute n=8 finding. The conclusion in the title — bread as a treatment for diabetes — outruns the design. The methods point stands: when flavor is masked, blinding becomes possible, and the insulin excursion can still move. Bread and chapati papers (Losso et al., 2009, and later culinary reports) are formulation experiments. They are not a second pharmacology.

Extracts leave the kitchen. Gupta et al., 2001 used 1 g/day of a hydro-alcoholic seed extract for two months in 25 newly diagnosed type 2 patients. Fasting and two-hour glucose did not differ from placebo; areas under the glucose and insulin curves were reported lower, and triglyceride and HDL moved. Chevassus et al., 2009 and 2010 used hydro-alcoholic extracts at 588 and 1176 mg, then at a fixed extract dose, for fat-intake endpoints. Lu et al., 2008 used total saponins as six pills three times daily on top of a sulfonylurea. None of these is 10 g of soaked seed. Collapsing them into one “fenugreek arm” in a meta-analysis is how a viscous-fiber food and a saponin tablet become a single weighted mean difference.

09 Standardization

Standardization is a commercial sentence about a marker, not a proof that the marker is the active. A powder standardized to nothing is still a powder; its uncontrolled variables are cultivar, soak, and grind. An extract standardized to 20% protodioscin (Furosap) or to “>45% furostanolic saponins” (a Fenfuro label claim in Gupta et al., 2024) is a different object. Fenuside is the Gencor/Testofen saponin-glycoside standardization name. A PubMed Title/Abstract search for Fenuside as a separately indexed trial product does not recover an independent literature. Fenuside is a fraction name inside Testofen, not a second evidence base.

What a marker does not do is travel backward to the seed. If a 600 mg Testofen capsule is a specialized glycoside fraction, the kitchen tablespoon is not a dilute Testofen. If Furosap is 20% protodioscin, the defatted 100 g flour in Sharma et al., 1990 is not a megadose of Furosap; it is mostly fiber and protein. If Fenfuro is sold for glucose and Furocyst for polycystic ovary syndrome and Libifem for women, those are marketing partitions of related extract families. They are not three independently discovered pharmacologies. Section 10 names the brands so that Section 11 can forbid the usual swap.

Analytical ranges for 4-hydroxyisoleucine, diosgenin, and trigonelline vary by cultivar and by extraction solvent. This article does not print a typical-mg/g table as if it were a certified assay. Roberts, 2011 and LactMed supply review-level inventories. They are good enough to say the classes exist. They are not good enough to convert a seed powder into a stated milligram dose of any one marker. When a trial does not name a brand or a marker, the honest description is the description in the paper: powder, soaked seed, hydro-alcoholic extract, total saponins, or “specialized seed extract.”

10 Proprietary extracts

A small set of commercial laboratories and recurring author groups accounts for most of the branded literature. That is a fact about the file, not an accusation that every result is false. It is a reason to refuse generalization and to keep open-label one-arm studies in a separate bin from placebo-controlled trials.

Testofen (Gencor; Fenuside glycoside fraction) is the specialized seed extract used at 600 mg/day in the Steels/Rao male-libido and aging-male trials (Steels et al., 2011; Rao et al., 2016). Steels added minerals. Testosterone remained within the reference range; subjective sexual-function domains moved. Rao reported increases in total and free testosterone versus placebo in healthy men aged 43–70, with Aging Male Symptoms and sexual-function scores. The investigator family is the same. The product is not culinary seed. Pickering et al., 2022 later used a 500 mg/day specialized seed extract from the same commercial orbit in prediabetes; week-12 fasting and post-prandial glucose and triglycerides differed between groups, while HbA1c, insulin, and C-peptide did not. That paper is an exploratory extract trial. It is not a seed-powder replication of Rafraf or Sharma.

Fenu-FG is an Indus Biotech glycoside used at 300 mg twice daily during eight weeks of supervised resistance training (Wankhede et al., 2016). The authors reported anabolic and androgenic activity versus placebo and a body-fat change without loss of strength. The paper is a pilot. A corrigendum exists (Wankhede et al., 2020). Any numerical claim should be read from the corrected record of the abstract. This is not Testofen, not Furosap, and not 10 g of powder.

Furosap is a Cepham/Chemical Resources extract labelled at 20% protodioscin and studied at 500 mg/day in open-label, one-arm series of men (Maheshwari et al., 2017; Sankhwar et al., 2023). Free testosterone and sperm parameters are reported as responder percentages or as uncontrolled before–after changes. Safety laboratories were described as unremarkable. Without a placebo, a 12-week male sexual-health study is an emerging commercial signal, not a confirmation of Rao 2016, and not evidence about seed powder.

Fenfuro is a furostanolic-saponin extract studied as a glycemic add-on. Verma et al., 2016 randomized 154 adults with type 2 diabetes to Fenfuro 500 mg twice daily or placebo for 90 days. The paper reports responder rates for fasting and post-prandial glucose and a reduction in anti-diabetic dose in a higher fraction of the extract arm. HbA1c fell in both groups. Cepham/Bagchi conflicts of interest are on the paper. Responder-rate reporting is not a mean difference. Gupta et al., 2024 reported a later double-blind add-on trial of 1000 mg/day Fenfuro on metformin with or without a sulfonylurea. Abstract percentages for fasting glucose, post-prandial glucose, and HbA1c are large for an add-on extract. This review did not treat those percentages as load-bearing numbers pending PDF-table verification. The trial is recorded as an industry-linked Fenfuro study. It is not used here as a benchmark effect size.

Furocyst is a related furostanolic-saponin extract, labelled near 40%, studied in polycystic ovary syndrome. Swaroop et al., 2015 was open-label and one-arm (50 women, 90 days, 500 mg twice daily): ovary volume, cyst size, menstrual regularity, and a 12% pregnancy figure are before–after claims. Singh et al., 2022 reported a larger double-blind, placebo-controlled study (208 completers) with Chemical Resources authorship and a wide claim set — cysts, volume, hirsutism, cycle regularization, gonadotropins, lipids, HOMA, free testosterone. That is an emerging proprietary file. It is not Younesy’s seed-powder dysmenorrhea trial, and it is not a metformin-replacement study.

Libifem is the same extract family directed at women. Rao et al., 2015 used 600 mg/day for two menstrual cycles in 80 women aged 20–49 with low sexual drive; free testosterone and estradiol rose, and desire and arousal scores improved versus placebo. Rao et al., 2023 combined Libifem at 600 or 300 mg/day with an eight-week training programme; the 600 mg arm showed a greater leg-press one-repetition maximum and a fat-mass change versus placebo. RDC Clinical employees are on the paper. Exercise is a confounder. Libifem is not Testofen by label, and it is not culinary seed. It is the female-facing product from the same commercial neighbourhood.

Two further named products sit on the edge of this cluster. TrigozimR is a fenugreek extract plus essential nutrients, dose-ranged at 0, 600, 1200, and 1800 mg in Lee-Ødegård et al., 2024. Plasma testosterone and free-testosterone index rose versus baseline and did not versus placebo. Salivary testosterone was the residual positive. Commercial laboratory involvement is disclosed. The paper is the best cautionary RCT in the androgen file; Section 17 returns to it. A de-husked 600 mg extract in menopausal women (Steels et al., 2017) and a 250 mg-twice-daily protodioscin:trigonelline 3:1 extract in perimenopause (Khanna et al., 2020) are additional proprietary objects. They are not seed powder, and Khanna’s six-week hormone swings are treated cautiously.

Poole et al., 2010 and Wilborn et al., 2010 are the Torabolic-era resistance-training pair: 500 mg/day of a commercial extract in trained young men, with body-fat and strength signals and, in Wilborn, a testosterone difference versus placebo. Wilborn’s title does not name fenugreek; it names a purported aromatase and 5α-reductase inhibitor. This article treats that paper as a companion extract trial from the same era, not as unnamed seed powder. Mixed botanicals — fenugreek plus ginger plus turmeric (Bumrungpert et al., 2018), or fenugreek plus Lespedeza cuneata — are not fenugreek monotherapy and are not listed here as extract brands.

11 The generalization error

The error is easy to state and hard to keep out of secondary prose. A reviewer writes “fenugreek improves glucose” and cites Sharma 100 g, Gupta 1 g extract, Rafraf 10 g powder, Verma Fenfuro 500 mg twice daily, and Pickering 500 mg specialized extract as if they were one intervention at different doses. They are not. The milligram column is not a potency series. It is a product series. Food-level seed and fiber carry the replicated glycemic and lipid signal, with high heterogeneity and generally low trial quality (Neelakantan et al., 2014; Gong et al., 2016; Shabil et al., 2023). Proprietary saponin extracts carry the androgen, libido, PCOS, and some glycemic-add-on claims, with industry gravity and, in Lee-Ødegård et al., 2024, a plasma-testosterone signal that dies against placebo. Isolated 4-hydroxyisoleucine carries a beautiful islet paper and no human RCT. Those three sentences cannot be averaged.

Meta-analyses that mix the products inherit the error as I². Neelakantan et al., 2014 and Gong et al., 2016 reported fasting-glucose reductions; Shabil et al., 2023, with a different trial set, did not find a significant fasting-glucose effect and still found an HbA1c reduction. That instability is not a scandal. It is what a mixed product class looks like when trial quality is low. The correct reader move is to ask which product, in which population, at which reported amount, for which duration — and then to refuse the spice-jar inference from Testofen and the Testofen inference from the spice jar.

Figure 3 is the inequivalence the rest of the article enforces. Every later results sentence names the form. Where a secondary source does not, this document does not repair the omission by assuming seed.

12 Glycemic control

Glycemia is the most replicated human signal in this file. It is also the noisiest. The honest grade is strongly supported for a modest glucose-lowering effect of food-like seed or fiber-rich preparations in people with diabetes or high diabetes risk, and emerging or weaker for low-dose proprietary extracts. Trial quality is generally low. Heterogeneity is high. Meta-analyses do not agree on fasting glucose. Those four sentences are the section. The paragraphs below are the evidence, not a rescue of a marketing line.

The classical food-level papers are old, small, and hard to blind. Sharma et al., 1990 randomized isocaloric diets, ten days each, in insulin-treated type 1 diabetes, using 100 g/day defatted seed powder split into lunch and dinner. Fasting glucose fell. The glucose-tolerance curve improved. Twenty-four-hour urinary glucose fell by 54%. Total cholesterol, LDL/VLDL, and triglycerides fell; HDL did not. The PubMed abstract does not state n. Ten days is short. One hundred grams is a food, not a capsule. Odor and taste unblinding are almost certain. The paper remains the most cited seed-flour result in type 1 diabetes, and it remains a 100 g finding. Madar et al., 1988 gave 15 g powdered seed soaked in water as an acute meal-tolerance test in non-insulin-dependent diabetes. Post-prandial glucose fell. Insulin trended lower and was not significant. Lipids at three hours did not move. n is again missing from the abstract. These two papers establish that large, recognizable seed loads can move glucose in diabetic populations. They do not establish a supplement.

Later powder trials are closer to a modern RCT shape and still smell of the seed. Rafraf et al., 2014, in a triple-blind eight-week trial of 88 adults with type 2 diabetes, compared 10 g/day whole-seed powder with 5 g/day wheat starch. Fasting glucose, HbA1c, insulin, HOMA-IR, total cholesterol, and triglycerides fell relative to placebo; adiponectin rose; LDL and HDL did not differ. This is one of the cleaner seed-powder trials. It is still a single-center 10 g powder. Hassani et al., 2019 compared 5 g powder twice daily with a wheat-flour placebo for two months in 62 adults and reported between-group differences in fasting glucose, HbA1c, body-mass index, waist circumference, diastolic pressure, and quality of life. Wheat flour does not smell of sotolon. Hadi et al., 2020 randomized 50 adults to 5 g powder three times daily (15 g/day) plus usual care for eight weeks; fasting glucose fell versus control as a secondary finding in a trial whose primary aims were irisin, blood pressure, and liver and kidney tests. Hadi is also a co-author on the Askarpour lipid meta-analysis. The paper is not a second dedicated HbA1c programme and is not counted here as one.

Open or single-blind dietary add-ons stretch the same powder story across years and across vehicles. Gaddam et al., 2015 followed 66 fenugreek and 74 control participants with prediabetes for three years on 5 g powder twice daily (10 g/day) before meals. Cumulative diabetes incidence was lower on fenugreek; fasting and post-prandial glucose and LDL fell; insulin rose. Controls were reported to have a 4.2-fold higher chance of progressing to type 2 diabetes. The trial is long and not described as placebo-blinded. A relative-risk claim of that size from an open dietary add-on needs PDF-level verification before it is treated as a prevention effect size; this article records the direction and the design, not the 4.2 as a settled number. Kassaian et al., 2009, already discussed, made the vehicle the result: hot water moved fasting glucose and triglycerides, yoghurt did not. Ranade and Mudgalkar, 2017 found late, isolated p values in a six-month single-blind soak. None of these papers rescues Sharma’s 100 g, and none of them is Fenfuro.

Extracts are not a small powder. Gupta et al., 2001, in 25 newly diagnosed type 2 patients (fasting glucose below 200 mg/dL), compared 1 g/day hydro-alcoholic extract with placebo for two months. Fasting and two-hour glucose did not differ between groups. Areas under the glucose and insulin curves were reported lower, HOMA beta-cell and sensitivity indices moved, and triglycerides and HDL moved. The sample is tiny. Abstract area-under-curve figures in the PubMed record look internally inconsistent and are not quoted here. The paper is useful as a negative on fasting glucose at extract scale. Lu et al., 2008 added total saponins, six pills three times daily, to continued sulfonylurea for 12 weeks in 69 adults (46 extract, 23 placebo). Fasting and two-hour glucose, HbA1c, and symptom scores improved versus placebo; body-mass index and hepatic and renal tests did not differ. That is a saponin add-on in a Chinese integrative-medicine setting, not a seed-flour replication. Pickering et al., 2022, exploratory and commercially associated, found week-12 fasting and post-prandial glucose and triglyceride differences on 500 mg/day specialized extract in prediabetes, with HbA1c, insulin, and C-peptide non-significant.

Fenfuro occupies its own bin. Verma et al., 2016, a multicenter, randomized, placebo-controlled, 90-day add-on in 154 adults, reported that more Fenfuro than placebo subjects had a fasting or post-prandial decrease and that 48.8% versus 18.05% reduced their anti-diabetic dose. HbA1c fell in both groups. Conflicts of interest run through Cepham and Bagchi. Responder rates are not means. A later Fenfuro add-on paper (Gupta et al., 2024) describes very large within-treatment changes in fasting glucose, post-prandial glucose, and HbA1c. Those percentages are not used as load-bearing numbers in this article. Extreme extract effect sizes in industry-linked journals are a reason to wait for tables, not a reason to rewrite the seed-powder file.

Geberemeskel et al., 2019 must be read by its endpoints, not its title. Newly diagnosed type 2 patients (n=114) received 25 g seed-powder solution twice daily or metformin for one month. The reported results are lipids: total cholesterol, triglycerides, and LDL down, HDL up, versus baseline and versus metformin, with unchanged lipids on the control side. The title says antidiabetic. The abstract that this review verified is a lipid abstract. Unblinded active comparison, a single Ethiopian center, and 30-day effect sizes that are large for any dietary powder are all reasons not to promote the paper as a glucose trial. It is filed under lipids (Section 14) as well as here, so that the title cannot launder the endpoint.

The meta-analyses disagree in a way that is more informative than any single trial. Neelakantan et al., 2014 pooled ten trials of at least one week and reported fasting glucose −0.96 mmol/L (95% CI −1.52 to −0.40; I²=80%), two-hour glucose −2.19 mmol/L (−3.19 to −1.19; I²=71%), and HbA1c −0.85% (−1.49 to −0.22; I²=0%; three trials). Effects sat mainly in diabetes at medium or high dose. The authors judged most trials of low methodological quality. Gong et al., 2016, mixing forms across ten articles / twelve studies, reported fasting glucose −0.84 mmol/L, two-hour glucose −1.30, HbA1c −1.16, and total cholesterol −0.30 mmol/L, with gastrointestinal discomfort as the main adverse effect and no liver or kidney toxicity in the included trials. Kim et al., 2023 (ten RCTs, 706 participants) again found reductions in fasting glucose, two-hour glucose, and HbA1c, with HOMA-IR non-significant, some lipid movement, LDL and body-mass index non-significant, and mild gastrointestinal events. Shabil et al., 2023, fourteen trials and 894 participants, is the qualifying paper: fasting glucose was not significant (mean difference 3.70; 95% CI −27.02 to 19.62; p=0.76), post-prandial glucose was not significant, and HbA1c still fell (−0.88; −1.49 to −0.27). Vajdi et al., 2024, nineteen studies, reported larger weighted mean differences on fasting glucose, HbA1c, HOMA-IR, total cholesterol, LDL, body-mass index, and HDL, with insulin, triglycerides, and weight non-significant. Product heterogeneity is the shared limitation. Neelakantan, Gong, and Kim are not cancelled by Shabil. Shabil is not cancelled by Vajdi. The fasting-glucose claim is unstable under re-pooling. The HbA1c claim is more durable and still sits on a small, mixed, low-quality base. That is strongly supported as a directional human signal. It is not a drug-class effect size, and it is not established as a property of every capsule labelled fenugreek.

13 Fiber versus unique phytochemistry

The marketing sentence is that fenugreek contains a unique amino acid and unique saponins, and that those molecules explain the glucose effect. The experimental sentence, from the dog fractions and from human fiber and extract intake work, is more boring and more defensible. Viscous galactomannan can blunt post-prandial glucose and can change satiety without any requirement that 4-hydroxyisoleucine reach an islet. Saponins can move cholesterol in animals and can be concentrated into branded extracts that then acquire their own, mostly industry-entangled, endpoint literature. Isolated 4-hydroxyisoleucine can potentiate glucose-induced insulin release in islets. Those are three different warrants. They are not a cascade in which the third explains the first.

Ribes et al., 1986 is still the cleanest split: fiber-rich testa and endosperm lowered hyperglycemia in diabetic dogs; saponin-and-protein cotyledons did not. Srichamroen et al., 2009 showed viscosity-paralleled inhibition of intestinal glucose uptake ex vivo. Mathern et al., 2009 isolated the fiber and gave 0, 4, or 8 g with breakfast to 18 healthy obese adults in a single-blind crossover. Eight grams increased satiety and fullness and reduced hunger and prospective consumption. Palatability fell with dose. Glucose area-under-curve did not fall. Insulin area-under-curve rose at 8 g. Lunch intake was lower for 8 g than for 4 g and not significantly lower than control. Rest-of-day energy did not change. Satiety was not explained by a flatter glucose curve. Isolated fiber is not whole seed, and it is not 4-hydroxyisoleucine, and in this breakfast it did not even produce the glucose result that reviews later attribute to “fenugreek.”

Chevassus et al., 2009 and 2010 are the papers most often misfiled as human 4-hydroxyisoleucine. They are hydro-alcoholic seed extracts. In twelve healthy men, a three-period crossover of 14 days plus washout, 1176 mg/day reduced spontaneous fat intake by 17.3% versus placebo (3.73 versus 4.51 MJ/day, p=0.038). Total energy fell 11.7% and missed significance. Weight, glucose, insulin, lipids, and visual-analogue appetite scores did not move. In 39 overweight men, six weeks of a fixed extract dose reduced the fat-intake ratio to total energy expenditure (0.26 versus 0.30, p=0.032) and the insulin/glucose ratio (0.89 versus 1.06 mU/mmol, p=0.044), with weight, appetite scores, and oxidative markers unchanged. Small, short, extract, possible odor. Not an isolate RCT. The human-isolate file remains empty.

Petit et al., 1995 then forbids the remaining slogan. Purified fenugreek saponins increased food intake in rats. Fiber increased satiety in Mathern’s humans. Extract reduced fat intake in Chevassus’s humans. “Fenugreek and appetite” is not a single arrow. Uemura’s diosgenin work in mice and 3T3-L1 cells (Uemura et al., 2010) and Broca’s ID-1101 clamps (Broca et al., 2004) are plausible mechanisms for adipose inflammation and insulin signaling. They are not substitutes for a human isolate trial, and they are not required to explain why 10 g of viscous seed powder might lower a post-prandial excursion. Fuller and Stephens, 2015 already refused a definitive therapeutic role for the three-constituent model. The refusal is still the correct grade: fiber as mechanism is strongly supported; unique phytochemistry as the necessary explanation of human glucose change is plausible and unproven; isolated 4-hydroxyisoleucine as a human drug is speculative.

14 Lipids

Lipid benefit is strongly supported for total cholesterol at the meta-analytic level and weaker for the rest of the panel. It is smaller and less consistent than the glycemic claim in the same reviews, and it is weight-neutral in the dedicated lipid meta-analysis. Sharma et al., 1990 already moved total cholesterol, LDL/VLDL, and triglycerides in ten days of 100 g defatted flour, without moving HDL. Geberemeskel et al., 2019, despite an antidiabetic title, is a one-month lipid paper at 25 g seed-powder solution twice daily versus metformin, with large percentage changes that this article records as a single-center unblinded signal rather than as a benchmark. Rafraf et al., 2014 moved total cholesterol and triglycerides at 10 g/day and did not move LDL or HDL. Kassaian’s hot-water arm moved triglycerides and VLDL; the yoghurt arm did not. The primary papers already disagree about which line on the panel moves.

Askarpour et al., 2020 pooled 12 RCTs (14 arms, 560 adults) and reported total cholesterol −9.37 mg/dL, triglycerides −13.78, LDL −6.59, and HDL +3.50. Weight and body-mass index did not change. Mixed forms and doses are the first limitation. Hadi as co-author is the second: this is not an independent second Hadi glycemic paper. Khodamoradi et al., 2020, in a cardiometabolic meta-analysis of 12 articles, found fasting glucose −12.94 mg/dL (I²=85%), HbA1c −0.58%, total cholesterol −9.13, and LDL −11.11, with other cardiometabolic parameters non-significant, and urged caution. Gong et al., 2016 had left triglycerides, LDL, and HDL uncertain. Kim et al., 2023 improved total cholesterol, triglycerides, and HDL and left LDL and body-mass index non-significant. Vajdi et al., 2024 reported large lipid weighted mean differences that sit above Askarpour and should be read as product-heterogeneous, not as a new physiology. The durable sentence is: seed or mixed fenugreek products are associated with a small total-cholesterol reduction and a weight-neutral body-weight file. HDL and triglyceride claims flip with the review. Unique saponin chemistry is a plausible contributor (Sauvaire et al., 1991; Petit et al., 1995). Viscous fiber is a sufficient contributor. Neither has been isolated as the human lipid mechanism.

15 Appetite

Human appetite data are emerging and small. They are also the section most often rewritten as a 4-hydroxyisoleucine story. Chevassus et al., 2009, twelve healthy men, hydro-alcoholic extract, 14-day periods: high dose cut fat intake 17.3% versus placebo; total energy was a non-significant 11.7% lower; visual-analogue appetite scores did not move; weight, glucose, insulin, and lipids did not move. Chevassus et al., 2010, 39 overweight men, six weeks, fixed extract: fat intake relative to expenditure fell; the insulin/glucose ratio fell; weight and appetite scores did not. Mathern et al., 2009, isolated fiber, 18 obese adults, one breakfast: 8 g raised satiety and lowered palatability; glucose did not fall; insulin rose; lunch was not significantly lower than control; the rest of the day was unchanged. Three papers. Two products. No isolate. No weight loss. Petit’s rat saponins went the other way. The correct grade is a small, extract-or-fiber, fat-or-satiety signal that does not survive translation into a weight claim. Askarpour et al., 2020 already found weight and body-mass index unchanged across lipid trials. Appetite papers that do not move weight are not a contradiction of Askarpour. They are the same fact from the intake side.

16 Lactation

Lactation is the claim that most needs a ceiling, because the cultural warrant is older than the trials. The ceiling is Foong et al., 2020. The Cochrane review of oral galactagogues in mothers of non-hospitalised term infants judged natural galactagogues at very low certainty, could not meta-analyse fenugreek infant weight or milk volume because heterogeneity was too high, and listed maple-syrup-smelling urine among reported adverse effects. Pharmacologic galactagogues had a low-certainty increase in milk volume. That is the evidence grade this article will not outrun. Forinash et al., 2012, before Cochrane, had already called fenugreek results mixed and the trials small, and had told clinicians to exhaust non-drug measures first. LactMed (chapter 30000838) states that a galactagogue effect may be primarily psychological, notes that two meta-analyses disagree, and records a United States survey in which 43% of users thought supply increased, 5% thought it decreased, and 45% of 85 users reported an adverse effect. Sim et al., 2015, in qualitative interviews with 20 women, found confidence and self-empowerment as themes: perceived adequacy was often psychological in the absence of measured volume. Those secondary and qualitative sources do not prove expectancy. They forbid treating expectancy as a cynical afterthought.

The primary papers that survive title-checking do not lift Cochrane. Turkyilmaz et al., 2011 randomized 66 mother–infant pairs in the first week to a herbal tea containing fenugreek, an apple placebo tea, or no tea. Maximum weight loss was lower, birth-weight was regained earlier, and day-3 milk volume was higher versus both comparators. The product is a tea, not an isolated seed or a standardized extract. The fenugreek brand and amount are not a Testofen-style marker. The window is the first week. Sotolon makes blinding of a fenugreek tea structurally weak even when a placebo tea is named. Bumrungpert et al., 2018 randomized 50 exclusively breastfeeding mothers to mixed capsules of fenugreek plus ginger plus turmeric, three capsules three times daily, or placebo for four weeks. Milk volume was 49% higher at week 2 and 103% higher at week 4 versus a greater-than-placebo comparison; nutrient content did not change; adverse events were similar. The mixture cannot be attributed to fenugreek. Khan et al., 2018, a network meta-analysis of five studies and 122 fenugreek-exposed mothers, reported a weighted mean difference versus placebo of +11.11 mL (6.77–15.46) and a pairwise +17.79 mL. The absolute millilitres are modest. Coleus amboinicus and palm date ranked higher. Comment and erratum literature exists around this network. It is not a large, clean fenugreek effect.

Rouhi et al., 2025, a triple-blind trial in 68 mothers of preterm infants under 32 weeks, compared 500 mg fenugreek with placebo three times daily from days 5 to 14. Day-7 milk volume was higher (p=0.017). Day-15 volume was not. Prolactin was not. Infant weight was not. Satisfaction was not. Adverse events were not reported as a problem. An early volume signal that is gone a week later, without a prolactin change, is not a mechanism confirmation and is not a sustained galactagogue effect. Reeder and colleagues (Clinical Lactation, 2013) studied fenugreek in mothers of preterm infants and are widely cited in lactation reviews. The paper is not PubMed-indexed. It is not assigned a PMID here and is not used as a load-bearing trial. The lactation file, taken together, is emerging at best and, after Cochrane, closer to not established as a reliable galactagogue. Mixed herbs, teas, short windows, modest millilitres, expectancy, and odor are the qualifications that have to travel with every positive sentence.

17 Testosterone and libido

Androgen and libido claims are the commercial center of gravity and the weakest scientific one. The grade is emerging for proprietary extracts on subjective sexual-function scores in industry-linked trials, and not established for a reliable rise in plasma testosterone versus placebo, especially not for culinary seed. Steels et al., 2011 randomized 60 healthy men aged 25–52, without erectile dysfunction, to Testofen 600 mg/day plus minerals or placebo for six weeks. DISF-SR arousal and orgasm domains rose. Self-rated muscle strength, energy, and well-being improved. Prolactin and testosterone remained within the reference range. The product is Testofen plus minerals, not extract alone, not seed, and not a testosterone-raising trial. Rao et al., 2016, same investigator family, randomized 120 healthy men aged 43–70 to Testofen 600 mg/day or placebo for 12 weeks. Aging Male Symptoms scores and sexual-function items (morning erections, activity) improved. Total and free testosterone increased versus placebo. That is the paper the market wanted. It remains one commercially associated extract trial in healthy aging men. It does not license the spice jar.

Open-label Furosap series then inflate the same claim without a control. Maheshwari et al., 2017, 50 men, 12 weeks, 500 mg/day (20% protodioscin): free testosterone “improved up to 46% in 90%” of subjects; sperm counts improved in 85.4%; mood, alertness, and libido improved by self-report; safety laboratories were described as unremarkable. Sankhwar et al., 2023, 100 men, same product and duration: free and bound testosterone improved at 12 weeks; sperm motility rose; abnormal morphology fell; LDL fell; mood and libido improved; no adverse events were reported. Responder percentages without a placebo are not a replication of Rao 2016. They are the same commercial lineage talking to itself.

Lee-Ødegård et al., 2024 is the paper that should have ended the uncritical testosterone sentence. Ninety-five men aged 40–80 completed a 12-week double-blind trial of TrigozimR at 0, 600, 1200, or 1800 mg plus nutrients. Plasma testosterone and free-testosterone index rose versus baseline and did not versus placebo (p=0.122 and 0.059). Salivary testosterone rose versus baseline and versus placebo (31.1% and 37.2%); at 1800 mg, salivary testosterone was +19.6% (p=0.006). There were no subjective or side-effect differences. Vitas/DBG commercial involvement is disclosed. Plasma testosterone is the endpoint the market cites. Against placebo, it died. Saliva is the residual claim. Subjective benefit did not appear. This is not an independent academic masterpiece. It is the best-controlled caution in the file, and it is enough to forbid treating extract testosterone as established.

Mansoori et al., 2020 meta-analysed four extract RCTs to November 2018 and found a significant effect on total serum testosterone. Four trials is a thin base. Extract-only is the inclusion rule. Smith et al., 2021, reviewing 32 RCTs across 13 herbs, listed fenugreek seed extracts and ashwagandha as the two herbs with positive testosterone signals; nine of 32 studies across the whole herb set increased testosterone, and six of 32 had low risk of bias. Many samples were young and non-clinical. A four-trial extract meta-analysis and a mixed-herb systematic review do not convert Testofen into seed powder and do not outrun Lee-Ødegård on plasma testosterone versus placebo. Libifem in women (Rao et al., 2015) moved free testosterone, estradiol, and sexual-function scores at 600 mg/day over two cycles. That is the same extract family, a subjective sexual endpoint, and the same investigator neighbourhood. It is not a male-enhancement warrant, and it is not culinary fenugreek.

18 Strength and body composition

Strength and composition data are emerging, extract-bound, and entangled with training. Poole et al., 2010 randomized 49 resistance-trained men to 500 mg/day of a commercial fenugreek extract or placebo during eight weeks of periodized training. Body fat fell 2.3 versus 0.39 percentage points. Leg-press one-repetition maximum rose 84.6 versus 48 kg. Bench rose 9.1 versus 4.3 kg. Wingate and endurance did not differ. Safety laboratories did not. Wilborn et al., 2010, 30 trained men, 500 mg/day of a product described as a purported aromatase and 5α-reductase inhibitor, reported a body-fat difference (−1.77 versus −0.55, p=0.048), a total-testosterone difference (+0.97 versus −2.10 ng/mL, p=0.018), and a bioavailable-testosterone difference, with estradiol showing a time main effect only. This article treats Wilborn as a companion Torabolic-era extract trial, not as seed powder, because the title does not name fenugreek. Wankhede et al., 2016 (Fenu-FG 300 mg twice daily, eight-week supervised training, 60 men) reported anabolic and androgenic activity and a body-fat change without loss of strength or repetitions. The abstract is qualitative on magnitudes. The corrigendum (Wankhede et al., 2020) is the record to read for numbers. Rao et al., 2023 added Libifem 600 mg/day to female training and reported a greater leg-press one-repetition maximum and a fat-mass change versus placebo; 300 mg did not separate from placebo on fat. Training is the shared confounder. Albaker-style narrative claims that fenugreek is a muscle agent rest on this thin RCT base. They do not license a spice-jar hypertrophy use, and they do not survive the Lee-Ødegård observation that a fenugreek extract can miss plasma testosterone and miss subjective effects in the same 12 weeks.

19 Menstrual symptoms and PCOS

The menstrual and ovarian file is two products pretending to be one indication. Younesy et al., 2014 randomized 101 students (51/50) to seed-powder capsules, 900 mg, two or three capsules three times daily on days 1–3 of two cycles, or placebo. Pain severity fell more than placebo. Pain duration fell across cycles only on fenugreek. Systemic symptoms — fatigue, headache, nausea — improved. No adverse events were reported. The sample is young and unmarried. Two cycles is short. Powder odor remains. The grade for primary dysmenorrhea is emerging on a single RCT, and it is a seed-powder finding, not a Furocyst finding.

Furocyst is the PCOS extract. Swaroop et al., 2015, open-label, one-arm, 50 premenopausal women, 500 mg twice daily for 90 days, reported smaller ovaries, reduced or dissolved cysts, more regular menses, a 12% pregnancy figure, higher LH and FSH, and a 94% “benefitted” sentence. Without a placebo, those percentages are promotional arithmetic. Singh et al., 2022 then supplied a double-blind, placebo-controlled study with 208 completers (113 Furocyst, 95 placebo) and a long list of improved cyst number, ovarian volume, hirsutism, menstrual regularization, LH/FSH, TSH, lipids, HOMA, and free testosterone. Chemical Resources authorship is on the paper. The claim set is large. Primary-endpoint discipline should be read from the PDF, not from the abstract’s inventory. The grade is emerging for a proprietary PCOS extract, industry-linked, and not transferable to seed powder or to Younesy.

Two other PCOS papers refuse a clean insulin-resistance win. Hassanzadeh Bashtian et al., 2013 added a hydro-alcoholic seed extract to metformin versus placebo plus metformin for eight weeks in 58 women. HOMA-IR, the primary, did not differ. Polycystic-appearing ovaries decreased and menstrual cyclicity improved. An add-on that fails its insulin-resistance primary is not a metformin substitute. A later active-comparator trial of fenugreek versus metformin exists in the broader literature; this review does not promote it as a placebo-controlled demonstration and does not treat fenugreek as interchangeable with metformin. Steels et al., 2017, a de-husked 600 mg extract in 115 randomized menopausal women (54/50 completed), improved MENQOL and vasomotor counts versus placebo; estradiol did not change. Khanna et al., 2020, 48 perimenopausal women, 250 mg twice daily of a protodioscin:trigonelline 3:1 extract for 42 days, reported large percentage falls in hot flushes, night sweats, depression, and insomnia, and large percentage swings in estradiol, free testosterone, progesterone, FSH, and SHBG. Akay affiliation, small n, and six-week hormone amplitudes are reasons to treat that paper as a cautious emerging signal, not as endocrine physiology. Menopause extracts are not Furocyst, not Younesy, and not Testofen, even when the author group overlaps.

20 Safety ledger

The safety conversation that the seed deserves is not the one the supplement aisle implies and not the one a careless herb list implies either. Fenugreek is not a typical hepatotoxin. LiverTox says so in those words (LiverTox chapter 31644133). It is a viscous, odorous Fabaceae seed that commonly upsets the gut, that can add to glucose-lowering drugs, that cross-reacts with peanut and chickpea, that has a documented warfarin-adjacent case literature, and that carries a pregnancy caution from animal developmental toxicity. A 2026 scoping review of human adverse effects (Amiri Ardekani et al., 2026) read 60 articles, found mild gastrointestinal events the most common, also listed hypoglycemia, possible hypokalemia, allergy, maple odor, and drug interactions, attributed no fatalities, and judged the seed generally considered safe. “Generally considered safe” is not a licence. It is a description of the counted file. This part keeps the ledger at the same volume as the efficacy claims in Part Three, and it refuses two distortions: fenugreek as a liver poison, and fenugreek as an inert food.

What is established: sotolon produces a maple-syrup odor of urine, sweat, and skin after ingestion, and that odor has triggered false maple syrup urine disease alarms in neonates and in herbal-tea drinkers (Bartley et al., 1981; Sewell et al., 1999; Podebrad et al., 1999; Korman et al., 2001). What is strongly supported: gastrointestinal intolerance as the modal adverse effect across Gong, Kim, LactMed, and the 2026 scoping review; IgE-mediated allergy with peanut and chickpea cross-reactivity (Patil et al., 1997; Faeste et al., 2009, 2010). What is plausible and clinically the right worry: additive hypoglycemia with insulin or insulin secretagogues, inferred from the glucose-lowering trials rather than from an ICU case series. What is emerging: anticoagulant interaction, on a boldo-plus-fenugreek re-challenge and a high-culinary-dose cirrhosis case, not on a controlled interaction programme. What is not supported as a class effect: hepatotoxicity. Rare modern herb–drug case reports do not reverse LiverTox.

21 Gastrointestinal effects and the odor that unblinds

Diarrhea, flatulence, nausea, and maple-smelling urine or sweat are the events the trials actually record. Gong et al., 2016 and Kim et al., 2023 both named gastrointestinal discomfort as the principal adverse effect and did not find hepatic or renal toxicity in the included studies. LactMed records maple odor from sotolon as a counseling fact and notes that a substantial fraction of surveyed galactagogue users reported some adverse effect. Amiri Ardekani et al., 2026 put mild gut events at the top of a 60-article human scoping review. Palatability falls as fiber dose rises (Mathern et al., 2009). None of this is mysterious. A viscous galactomannan at food-like grams, plus a potent furanone odorant, plus saponins, is a recipe for a recognizable, sometimes cramping, always fragrant intervention.

The same chemistry is a methods defect. Double-blind seed-powder trials that use wheat starch or wheat flour as placebo (Rafraf et al., 2014; Hassani et al., 2019) match color and perhaps texture. They do not match sotolon. Participants can smell which arm they are on. Investigators who handle the powder can smell which arm they are on. Outcome measures that are already subjective — satiety, libido, lactation adequacy, menopausal flushes, dysmenorrhea — sit on top of that leak. Bread and chapati incorporation can mask flavor (Losso et al., 2009) and is the exception that proves the rule. Extract capsules may leak less odor than 10 g of soaked seed, which is one reason the proprietary literature can look cleaner on paper than the powder literature. It is not a reason to trust extract blinding without asking. Section 26 returns to this as a red-team challenge. Here it is enough to say that gastrointestinal events and maple odor are not only safety items. They are the unblinding mechanism, and they are established as such.

The diagnostic trap is specific and does not require a large dose series. Bartley et al., 1981 reported maple-syrup urine odor after fenugreek ingestion. Sewell et al., 1999 described false diagnosis of maple syrup urine disease after herbal-tea ingestion. Podebrad et al., 1999 identified sotolon as the MSUD odorant and noted that it is also the fenugreek impact odorant. Korman et al., 2001 described newborns with maple-syrup odor after maternal prenatal or intrapartum fenugreek, explicitly linking fenugreek, maple syrup, and MSUD through sotolon. The neonates did not have the disease. They had the odorant. A newborn metabolic work-up triggered by fenugreek is a preventable error if the ingestion history is taken. Foong et al., 2020 listed maple-syrup-smelling urine among galactagogue adverse effects, which means the Cochrane authors treated the odor as a reported event, not as folklore. Figure 5 is that trap, not a dosing diagram.

22 Hypoglycemia and anticoagulants

This review did not recover a title-verified intensive-care hypoglycemia case series attributable to fenugreek. The clinical implication is still additive glucose lowering with sulfonylureas, metformin, or insulin, because those are the background drugs in the trials that moved glucose (Lu et al., 2008; Verma et al., 2016; Sharma et al., 1990; Hadi et al., 2020). Sharma’s 100 g defatted flour in insulin-treated type 1 diabetes is the most obvious setting in which an extra viscous-fiber load is not a spectator. Lu’s saponin add-on sat on a sulfonylurea. Verma’s Fenfuro paper reported a higher fraction of subjects reducing their anti-diabetic dose. Hadi’s 15 g/day powder moved fasting glucose as a secondary endpoint on usual care. The correct language is risk of additive hypoglycemia, not a documented epidemic of severe hypoglycemia. This document does not convert that risk into a monitoring schedule or a gram amount.

Anticoagulant evidence is thinner and more mixed than herb lists imply. Heck et al., 2000 listed fenugreek among botanicals that may increase bleeding risk or potentiate warfarin, largely on in-vitro or theoretical grounds. Lambert and Cormier, 2001 reported a rise in INR on boldo and fenugreek, normalization a week after stopping, and recurrence on reintroduction; the Naranjo score was “probable” for the combination. Fenugreek cannot be isolated from boldo in that case. Philips et al., 2018 described isolated severe coagulation failure in compensated cirrhosis after heavy fenugreek milk porridge, reversing when the porridge stopped and vitamin K was given. That is a single case at a high culinary dose in diseased liver. LactMed notes a warfarin interaction as a counseling point. The grade is plausible interaction, not established as a quantified potentiation, and not a reason to call the seed an anticoagulant. People already on vitamin-K antagonists are the population in which the case literature is relevant. This article does not turn that sentence into advice.

23 Allergy and Fabaceae cross-reactivity

Fenugreek is a legume. The allergy file is small, specific, and established as chemistry even if population prevalence remains unmeasured. Patil et al., 1997 reported two cases: inhalation produced rhinorrhea, wheezing, and syncope; a topical paste produced facial angioedema and wheeze. Skin tests were strong to fenugreek and chickpea. Double-blind, placebo-controlled food challenge dropped peak flow more than 20% after fenugreek and after chickpea. IgE-binding bands sat between 20 and 70 kD. Ohnuma et al., 1998 reported anaphylaxis to curry powder; fenugreek is a typical curry constituent, and the title does not isolate it. Joseph et al., 2018 described a clearly defined pediatric fenugreek anaphylaxis, where earlier child reports had been curry or paste with the agent unclear.

Faeste et al., 2009 tested 29 peanut- or legume-allergic sera and two skin-prick / oral-food-challenge cases. Most sera had high specific IgE to peanut and to fenugreek. Fenugreek sensitization was usually secondary to peanut. Primary fenugreek allergy was suspected in one. The oral-food-challenge eliciting dose was about 2 mg of native powder. Major bands sat at 50, 52, and 74 kD. About one third of fenugreek-containing foods were correctly labelled. Faeste et al., 2010 then used 13 dual-sensitized sera and mass-spectrometric proteomics: a 50–66 kD quintet, the 50 kD band strongest, with 7S-vicilin homology to Ara h 1 and 11S-legumin homology to Ara h 3, and possible 2S albumin and PR-10 contributions. That is a molecular basis for peanut cross-reactivity, not a prevalence study. LactMed repeats the chickpea and peanut cross-reaction as a lactation-counseling fact. The practical implication for this research review is narrow: a peanut-allergic population is the wrong population in which to treat fenugreek powder as a bland fiber. Two milligrams as an eliciting dose in a referred series is a laboratory and clinic fact, not a culinary recommendation.

24 Pregnancy

Pregnancy is a caution on animal evidence, not a counted human teratology series. Khalki et al., 2010 gave pregnant mice 500 and 1000 mg/kg/day aqueous extract throughout gestation. Dams showed no obvious toxicity. Offspring showed higher fetal death, smaller litters, lower fetal weight, and more morphological abnormalities. Those are high experimental amounts of an aqueous extract in a mouse. They are still developmental toxicity. Ouzir et al., 2016, reviewing toxicological properties, collected rodent, rabbit, and chick teratology, anecdotal human congenital reports, male testicular toxicity, and female anti-implantation or abortifacient activity attributed to saponins, and concluded that fenugreek is not recommended in pregnancy. Human congenital data remain thin. This article does not upgrade thin human anecdotes into a malformation rate, and it does not downgrade the animal file into folklore. The grade is strongly supported as a preclinical developmental-toxicity signal and plausible as a human pregnancy caution. It is not a completed obstetric epidemiology.

Korman et al., 2001 belongs beside Khalki, not inside it. Intrapartum or prenatal fenugreek produced neonatal maple odor and false MSUD suspicion. That is a diagnostic pitfall, not a teratology result. LactMed’s galactagogue doses and its psychological-effect sentence do not create a pregnancy indication. Cochrane’s very low certainty on natural galactagogues (Foong et al., 2020) is the lactation ceiling; the animal developmental file is the pregnancy ceiling. This document recommends no use in pregnancy because it recommends no use in anyone. It records the animal teratology so that a lactation or culinary anecdote cannot be mistaken for a reproductive-safety study.

Hepatotoxicity, to close the ledger where secondary lists sometimes open it, is not the fenugreek story. LiverTox (31644133): “Fenugreek has not been implicated in causing liver injury.” Amiri Ardekani et al., 2026 found no fatalities and no typical hepatotoxic pattern. Isolated modern reports of herb–drug transaminitis in people already on hepatically metabolized drugs are exceptions, not a class effect. Gong and Kim did not recover liver toxicity in the glycemic trials they pooled. The seed can still interact. It is not, on regulator-grade reading, a hepatotoxin.

25 Five research matrices

The tables below restated the file without repairing it. Amounts are reported study parameters, always with the population that received them. They are not instructions.

Glycemic matrix

Table 1. Glycemic. Food-like seed or fiber is the replicated cell. Fasting-glucose metas disagree. Fenfuro is not Sharma, and Gupta 2001 is not Rafraf.

Endocrine matrix

Table 2. Endocrine. Testosterone and libido signals cluster on named extracts. Plasma T versus placebo failed in Lee-Ødegård. Culinary seed is not in this table as an androgen product.

Lactation matrix

Table 3. Lactation. Cochrane is the ceiling. Teas and mixtures are not seed monotherapy. Reeder has no PMID.

Extract matrix

Table 4. Extract and form. If a results sentence does not name the row, it is not finished.

Safety matrix

Table 5. Safety at the same volume as efficacy. Gut, odor, allergy, and pregnancy caution carry the ledger. LiverTox closes the hepatotoxin narrative.

26 Adversarial resolution

These are the five attacks a careful reader is already making. They are answered from the tables, not from the seed’s reputation.

Do testosterone and male-enhancement claims survive?

Not as a property of fenugreek the spice, and only weakly as a property of named extracts. Steels et al., 2011 moved subjective sexual-function scores on Testofen plus minerals without taking testosterone out of range. Rao et al., 2016, same extract family, reported a testosterone rise versus placebo in healthy aging men. Furosap then repeated the claim without a placebo (Maheshwari et al., 2017; Sankhwar et al., 2023). Mansoori et al., 2020 needed only four extract trials to declare a total-testosterone effect. Lee-Ødegård et al., 2024 put a fenugreek extract against placebo with four doses and lost plasma testosterone and the free-testosterone index; saliva moved; subjective scores did not. That is the resolution. An industry-clustered extract literature can produce a testosterone sentence. It does not survive the best-controlled plasma comparison in the reviewed record, and it does not travel to 10 g of soaked seed or to a kitchen tablespoon. Male-enhancement marketing that treats those objects as one warrant is using the English name as a solvent.

What is the lactation evidence actually worth?

Very little, after Cochrane. Foong et al., 2020 rated natural galactagogues at very low certainty and could not pool fenugreek milk volume or infant weight. Turkyilmaz et al., 2011 is a first-week tea. Bumrungpert et al., 2018 is fenugreek plus ginger plus turmeric. Khan et al., 2018 finds about 11 mL versus placebo in a small network. Rouhi et al., 2025 finds a day-7 volume signal that is gone by day 15, without a prolactin change and without an infant-weight change. LactMed and Sim et al., 2015 leave room for a psychological effect. Reeder 2013 is not PubMed-indexed. The attack is correct: this is not a completed galactagogue file. It is a cultural practice with a thin, mixed, often multi-herb, often unblindable literature underneath it. This article will not write a lactation sentence that Cochrane already refused to meta-analyse.

Can a proprietary extract be generalized to the seed — or to other extracts?

No. That is the load-bearing error of the secondary literature. Testofen/Fenuside, Libifem, Furosap, Fenfuro, Furocyst, Fenu-FG, and TrigozimR are branded concentrates, often saponin-standardized, often from a short list of commercial laboratories and recurring authors (Steels/Rao; Bagchi/Swaroop/Cepham; Vitas). A 600 mg Testofen finding is not a 10 g powder finding and is not a 500 mg Furosap finding. Fenuside is a fraction name, not a second evidence base. Open-label Furosap and open-label Furocyst are not placebo-controlled confirmations of Rao or of Singh. Mixed botanicals are not monotherapy. Isolated 4-hydroxyisoleucine is not on the human map at all. Figure 3 and Table 4 are the resolution. If a review cites Sharma and Steels in the same “fenugreek raises” sentence, the sentence is already wrong.

Does odor and taste destroy blinding?

For powder and tea, structurally, yes. Sotolon is the impact odorant (Podebrad et al., 1999; Girardon et al., 1985). Wheat-starch and wheat-flour placebos do not smell of maple (Rafraf et al., 2014; Hassani et al., 2019). Soaked seed and fenugreek tea announce themselves. Gastrointestinal events announce themselves. Subjective endpoints — satiety, libido, milk adequacy, flushes, pain — are the endpoints most exposed to that leak. Losso et al., 2009 is the instructive exception: 5% fenugreek bread was sensory-indistinguishable from whole-wheat and still moved insulin area-under-curve in an acute n=8 crossover. Masking is possible. Most powder trials do not achieve it. Extract capsules may leak less, which can make the proprietary literature look more “double-blind” than the food literature without making it more true. Poor blinding is not a footnote on an otherwise clean file. It is a reason the glycemic signal, which has laboratory measures, is more trustworthy than the lactation and libido signals, which often do not.

Are glucose improvements just fiber, or unique phytochemistry?

Fiber is the sufficient explanation. Unique phytochemistry is the unpaid one. Ribes et al., 1986 assigned the dog glycemic effect to the testa–endosperm fiber fraction and not to the saponin-and-protein cotyledons. Srichamroen et al., 2009 paralleled glucose-uptake inhibition with viscosity. Mathern et al., 2009 isolated the fiber and got satiety without a glucose-area win and with an insulin-area rise. Neelakantan et al., 2014 saw effects mainly at medium or high seed doses in diabetes — the dose region where viscous fiber would be expected to work. Gupta et al., 2001, at 1 g of hydro-alcoholic extract, did not move fasting glucose. Shabil et al., 2023 lost the fasting-glucose meta-analytic signal while keeping HbA1c, which is what a mixed, low-quality, fiber-and-extract stew looks like. 4-Hydroxyisoleucine remains an established islet secretagogue without a human isolate RCT; Chevassus is extract. Saponins remain a plausible lipid and extract marker and, in Petit et al., 1995, an appetite-increasing fraction in rats. The attack is therefore half right and half overstated. Right: you do not need a unique amino acid to explain why 10 or 15 or 100 g of viscous seed powder might blunt glucose. Overstated: saponin extracts and 4-hydroxyisoleucine are not thereby shown to be inert. They are shown to be a different claim. This article keeps them different.

27 Standing constraint

28 References

1. Amiri Ardekani E, Parvizi MM, Zare R, Mosaffa Jahromi M, Rampp T, Pasalar M. Exploring the Adverse Effects of Fenugreek in Humans: A Scoping Review. Iran J Med Sci. 2026;51(1):4-18.
   PMID 41625343 · doi:10.30476/ijms.2025.106073.4017 · PMC12858439
2. Askarpour M, Alami F, Campbell MS, Venkatakrishnan K, Hadi A, Ghaedi E. Effect of fenugreek supplementation on blood lipids and body weight: A systematic review and meta-analysis of randomized controlled trials. J Ethnopharmacol. 2020;253:112538.
   PMID 32087319 · doi:10.1016/j.jep.2019.112538
3. Bartley GB, Hilty MD, Andreson BD, Clairmont AC, Maschke SP. "Maple-syrup" urine odor due to fenugreek ingestion. N Engl J Med. 1981;305(8):467.
   PMID 7254294 · doi:10.1056/NEJM198108203050823
4. Broca C, Gross R, Petit P, Sauvaire Y, Manteghetti M, Tournier M, et al.. 4-Hydroxyisoleucine: experimental evidence of its insulinotropic and antidiabetic properties. Am J Physiol. 1999;277(4):E617-23.
   PMID 10516120 · doi:10.1152/ajpendo.1999.277.4.E617
5. Broca C, Manteghetti M, Gross R, Baissac Y, Jacob M, Petit P, et al.. 4-Hydroxyisoleucine: effects of synthetic and natural analogues on insulin secretion. Eur J Pharmacol. 2000;390(3):339-45.
   PMID 10708743 · doi:10.1016/s0014-2999(00)00030-3
6. Broca C, Breil V, Cruciani-Guglielmacci C, Manteghetti M, Rouault C, Derouet M, et al.. Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat. Am J Physiol Endocrinol Metab. 2004;287(3):E463-71.
   PMID 15082420 · doi:10.1152/ajpendo.00163.2003
7. Bumrungpert A, Somboonpanyakul P, Pavadhgul P, Thaninthranon S. Effects of Fenugreek, Ginger, and Turmeric Supplementation on Human Milk Volume and Nutrient Content in Breastfeeding Mothers: A Randomized Double-Blind Controlled Trial. Breastfeed Med. 2018;13(10):645-650.
   PMID 30411974 · doi:10.1089/bfm.2018.0159
8. Chevassus H, Molinier N, Costa F, Galtier F, Renard E, Petit P. A fenugreek seed extract selectively reduces spontaneous fat consumption in healthy volunteers. Eur J Clin Pharmacol. 2009;65(12):1175-8.
   PMID 19809809 · doi:10.1007/s00228-009-0733-5
9. Chevassus H, Gaillard JB, Farret A, Costa F, Gabillaud I, Mas E, et al.. A fenugreek seed extract selectively reduces spontaneous fat intake in overweight subjects. Eur J Clin Pharmacol. 2010;66(5):449-55.
   PMID 20020282 · doi:10.1007/s00228-009-0770-0
10. Evans AJ, Hood RL, Oakenfull DG, Sidhu GS. Relationship between structure and function of dietary fibre: a comparative study of the effects of three galactomannans on cholesterol metabolism in the rat. Br J Nutr. 1992;68(1):217-29.
    PMID 1327099 · doi:10.1079/bjn19920079
11. Faeste CK, Namork E, Lindvik H. Allergenicity and antigenicity of fenugreek (Trigonella foenum-graecum) proteins in foods. J Allergy Clin Immunol. 2009;123(1):187-94.
    PMID 18930518 · doi:10.1016/j.jaci.2008.09.012
12. Faeste CK, Christians U, Egaas E, Jonscher KR. Characterization of potential allergens in fenugreek (Trigonella foenum-graecum) using patient sera and MS-based proteomic analysis. J Proteomics. 2010;73(7):1321-33.
    PMID 20219717 · doi:10.1016/j.jprot.2010.02.011 · PMC2894366
13. Foong SC, Tan ML, Foong WC, Marasco LA, Ho JJ, Ong JH. Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants. Cochrane Database Syst Rev. 2020;5(5):CD011505.
    PMID 32421208 · doi:10.1002/14651858.CD011505.pub2 · PMC7388198
14. Forinash AB, Yancey AM, Barnes KN, Myles TD. The use of galactogogues in the breastfeeding mother. Ann Pharmacother. 2012;46(10):1392-404.
    PMID 23012383 · doi:10.1345/aph.1R167
15. Fuller S, Stephens JM. Diosgenin, 4-hydroxyisoleucine, and fiber from fenugreek: mechanisms of actions and potential effects on metabolic syndrome. Adv Nutr. 2015;6(2):189-97.
    PMID 25770257 · doi:10.3945/an.114.007807 · PMC4352177
16. Gaddam A, Galla C, Thummisetti S, Marikanty RK, Palanisamy UD, Rao PV. Role of Fenugreek in the prevention of type 2 diabetes mellitus in prediabetes. J Diabetes Metab Disord. 2015;14:74.
    PMID 26436069 · doi:10.1186/s40200-015-0208-4 · PMC4591578
17. Geberemeskel GA, Debebe YG, Nguse NA. Antidiabetic Effect of Fenugreek Seed Powder Solution (Trigonella foenum-graecum L.) on Hyperlipidemia in Diabetic Patients. J Diabetes Res. 2019;2019:8507453.
    PMID 31583253 · doi:10.1155/2019/8507453 · PMC6748210
18. Girardon P, Bessiere JM, Baccou JC, Sauvaire Y. Volatile constituents of fenugreek seeds. Planta Med. 1985;51(6):533-4.
    PMID 17345286 · doi:10.1055/s-2007-969591
19. Gong J, Fang K, Dong H, Wang D, Hu M, Lu F. Effect of fenugreek on hyperglycaemia and hyperlipidemia in diabetes and prediabetes: A meta-analysis. J Ethnopharmacol. 2016;194:260-268.
    PMID 27496582 · doi:10.1016/j.jep.2016.08.003
20. Gupta A, Gupta R, Lal B. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. J Assoc Physicians India. 2001;49:1057-61.
    PMID 11868855
21. Hadi A, Arab A, Hajianfar H, Talaei B, Miraghajani M, Babajafari S, et al.. The effect of fenugreek seed supplementation on serum irisin levels, blood pressure, and liver and kidney function in patients with type 2 diabetes mellitus: A parallel randomized clinical trial. Complement Ther Med. 2020;49:102315.
    PMID 32147060 · doi:10.1016/j.ctim.2020.102315
22. Haefelé C, Bonfils C, Sauvaire Y. Characterization of a dioxygenase from Trigonella foenum-graecum involved in 4-hydroxyisoleucine biosynthesis. Phytochemistry. 1997;44(4):563-6.
    PMID 9041713 · doi:10.1016/s0031-9422(96)00620-6
23. Hassani SS, Fallahi Arezodar F, Esmaeili SS, Gholami-Fesharaki M. Effect of Fenugreek Use on Fasting Blood Glucose, Glycosylated Hemoglobin, Body Mass Index, Waist Circumference, Blood Pressure and Quality of Life in Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trials. Galen Med J. 2019;8:e1432.
    PMID 34466512 · doi:10.31661/gmj.v8i0.1432 · PMC8344183
24. Hassanzadeh Bashtian M, Emami SA, Mousavifar N, Esmaily HA, Mahmoudi M, Mohammad Poor AH. Evaluation of Fenugreek (Trigonella foenum-graceum L.), Effects Seeds Extract on Insulin Resistance in Women with Polycystic Ovarian Syndrome. Iran J Pharm Res. 2013;12(2):475-81.
    PMID 24250624 · PMC3813238
25. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm. 2000;57(13):1221-7; quiz 1228-30.
    PMID 10902065
26. Joseph NI, Slavin E, Peppers BP, Hostoffer RW. Fenugreek Anaphylaxis in a Pediatric Patient. Allergy Rhinol (Providence). 2018;9:2152656718764134.
    PMID 29977649 · doi:10.1177/2152656718764134 · PMC6028160
27. Kassaian N, Azadbakht L, Forghani B, Amini M. Effect of fenugreek seeds on blood glucose and lipid profiles in type 2 diabetic patients. Int J Vitam Nutr Res. 2009;79(1):34-9.
    PMID 19839001 · doi:10.1024/0300-9831.79.1.34
28. Khalki L, M'hamed SB, Bennis M, Chait A, Sokar Z. Evaluation of the developmental toxicity of the aqueous extract from Trigonella foenum-graecum (L.) in mice. J Ethnopharmacol. 2010;131(2):321-5.
    PMID 20600755 · doi:10.1016/j.jep.2010.06.033
29. Khan TM, Wu DB, Dolzhenko AV. Effectiveness of fenugreek as a galactagogue: A network meta-analysis. Phytother Res. 2018;32(3):402-412.
    PMID 29193352 · doi:10.1002/ptr.5972
30. Khanna A, John F, Das S, Thomas J, Rao J, Maliakel B, et al.. Efficacy of a novel extract of fenugreek seeds in alleviating vasomotor symptoms and depression in perimenopausal women: A randomized, double-blinded, placebo-controlled study. J Food Biochem. 2020;44(12):e13507.
    PMID 33025616 · doi:10.1111/jfbc.13507
31. Khodamoradi K, Khosropanah MH, Ayati Z, Chang D, Nasli-Esfahani E, Ayati MH, et al.. The Effects of Fenugreek on Cardiometabolic Risk Factors in Adults: A Systematic Review and Meta-analysis. Complement Ther Med. 2020;52:102416.
    PMID 32951700 · doi:10.1016/j.ctim.2020.102416
32. Kim J, Noh W, Kim A, Choi Y, Kim YS. The Effect of Fenugreek in Type 2 Diabetes and Prediabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int J Mol Sci. 2023;24(18).
    PMID 37762302 · doi:10.3390/ijms241813999 · PMC10531284
33. Korman SH, Cohen E, Preminger A. Pseudo-maple syrup urine disease due to maternal prenatal ingestion of fenugreek. J Paediatr Child Health. 2001;37(4):403-4.
    PMID 11532065 · doi:10.1046/j.1440-1754.2001.00617.x
34. Lambert JP, Cormier J. Potential interaction between warfarin and boldo-fenugreek. Pharmacotherapy. 2001;21(4):509-12.
    PMID 11310527 · doi:10.1592/phco.21.5.509.34492
35. Lee-Ødegård S, Gundersen TE, Drevon CA. Effect of a plant extract of fenugreek (Trigonella foenum-graecum) on testosterone in blood plasma and saliva in a double blind randomized controlled intervention study. PLoS One. 2024;19(9):e0310170.
    PMID 39288153 · doi:10.1371/journal.pone.0310170 · PMC11407615
36. Losso JN, Holliday DL, Finley JW, Martin RJ, Rood JC, Yu Y, et al.. Fenugreek bread: a treatment for diabetes mellitus. J Med Food. 2009;12(5):1046-9.
    PMID 19857068 · doi:10.1089/jmf.2008.0199
37. Lu FR, Shen L, Qin Y, Gao L, Li H, Dai Y. Clinical observation on trigonella foenum-graecum L. total saponins in combination with sulfonylureas in the treatment of type 2 diabetes mellitus. Chin J Integr Med. 2008;14(1):56-60.
    PMID 18219452 · doi:10.1007/s11655-007-9005-3
38. Madar Z, Abel R, Samish S, Arad J. Glucose-lowering effect of fenugreek in non-insulin dependent diabetics. Eur J Clin Nutr. 1988;42(1):51-4.
    PMID 3286242
39. Maheshwari A, Verma N, Swaroop A, Bagchi M, Preuss HG, Tiwari K, et al.. Efficacy of FurosapTM, a novel Trigonella foenum-graecum seed extract, in Enhancing Testosterone Level and Improving Sperm Profile in Male Volunteers. Int J Med Sci. 2017;14(1):58-66.
    PMID 28138310 · doi:10.7150/ijms.17256 · PMC5278660
40. Mansoori A, Hosseini S, Zilaee M, Hormoznejad R, Fathi M. Effect of fenugreek extract supplement on testosterone levels in male: A meta-analysis of clinical trials. Phytother Res. 2020;34(7):1550-1555.
    PMID 32048383 · doi:10.1002/ptr.6627
41. Mathern JR, Raatz SK, Thomas W, Slavin JL. Effect of fenugreek fiber on satiety, blood glucose and insulin response and energy intake in obese subjects. Phytother Res. 2009;23(11):1543-8.
    PMID 19353539 · doi:10.1002/ptr.2795
42. Neelakantan N, Narayanan M, de Souza RJ, van Dam RM. Effect of fenugreek (Trigonella foenum-graecum L.) intake on glycemia: a meta-analysis of clinical trials. Nutr J. 2014;13:7.
    PMID 24438170 · doi:10.1186/1475-2891-13-7 · PMC3901758
43. Ohnuma N, Yamaguchi E, Kawakami Y. Anaphylaxis to curry powder. Allergy. 1998;53(4):452-4.
    PMID 9574894 · doi:10.1111/j.1398-9995.1998.tb03924.x
44. Ouzir M, El Bairi K, Amzazi S. Toxicological properties of fenugreek (Trigonella foenum graecum). Food Chem Toxicol. 2016;96:145-54.
    PMID 27498339 · doi:10.1016/j.fct.2016.08.003
45. Patil SP, Niphadkar PV, Bapat MM. Allergy to fenugreek (Trigonella foenum graecum). Ann Allergy Asthma Immunol. 1997;78(3):297-300.
    PMID 9087156 · doi:10.1016/S1081-1206(10)63185-7
46. Petit PR, Sauvaire YD, Hillaire-Buys DM, Leconte OM, Baissac YG, Ponsin GR, et al.. Steroid saponins from fenugreek seeds: extraction, purification, and pharmacological investigation on feeding behavior and plasma cholesterol. Steroids. 1995;60(10):674-80.
    PMID 8539775 · doi:10.1016/0039-128x(95)00090-d
47. Philips CA, Augustine P. Rare cause of isolated severe coagulation failure in cirrhosis: traditional healing with fenugreek. BMJ Case Rep. 2018;2018.
    PMID 29330279 · doi:10.1136/bcr-2017-223479 · PMC5780598
48. Pickering E, Steels E, Rao A, Steadman KJ. An Exploratory Study of the Safety and Efficacy of a Trigonella foenum-graecum Seed Extract in Early Glucose Dysregulation: A Double-Blind Randomized Placebo-Controlled Trial. Pharmaceutics. 2022;14(11).
    PMID 36432644 · doi:10.3390/pharmaceutics14112453 · PMC9698270
49. Podebrad F, Heil M, Reichert S, Mosandl A, Sewell AC, Böhles H. 4,5-dimethyl-3-hydroxy-2[5H]-furanone (sotolone)--the odour of maple syrup urine disease. J Inherit Metab Dis. 1999;22(2):107-14.
    PMID 10234605 · doi:10.1023/a:1005433516026
50. Poole C, Bushey B, Foster C, Campbell B, Willoughby D, Kreider R, et al.. The effects of a commercially available botanical supplement on strength, body composition, power output, and hormonal profiles in resistance-trained males. J Int Soc Sports Nutr. 2010;7:34.
    PMID 20979623 · doi:10.1186/1550-2783-7-34 · PMC2978122
51. Rafraf M, Malekiyan M, Asghari-Jafarabadi M, Aliasgarzadeh A. Effect of Fenugreek Seeds on Serum Metabolic Factors and Adiponectin Levels in Type 2 Diabetic Patients. Int J Vitam Nutr Res. 2014;84(3-4):196-205.
    PMID 26098483 · doi:10.1024/0300-9831/a000206
52. Ranade M, Mudgalkar N. A simple dietary addition of fenugreek seed leads to the reduction in blood glucose levels: A parallel group, randomized single-blind trial. Ayu. 2017;38(1-2):24-27.
    PMID 29861588 · doi:10.4103/ayu.AYU_209_15 · PMC5954247
53. Rao A, Steels E, Beccaria G, Inder WJ, Vitetta L. Influence of a Specialized Trigonella foenum-graecum Seed Extract (Libifem), on Testosterone, Estradiol and Sexual Function in Healthy Menstruating Women, a Randomised Placebo Controlled Study. Phytother Res. 2015;29(8):1123-30.
    PMID 25914334 · doi:10.1002/ptr.5355
54. Rao A, Steels E, Inder WJ, Abraham S, Vitetta L. Testofen, a specialised Trigonella foenum-graecum seed extract reduces age-related symptoms of androgen decrease, increases testosterone levels and improves sexual function in healthy aging males in a double-blind randomised clinical study. Aging Male. 2016;19(2):134-42.
    PMID 26791805 · doi:10.3109/13685538.2015.1135323
55. Ribes G, Sauvaire Y, Da Costa C, Baccou JC, Loubatieres-Mariani MM. Antidiabetic effects of subfractions from fenugreek seeds in diabetic dogs. Proc Soc Exp Biol Med. 1986;182(2):159-66.
    PMID 2871558 · doi:10.3181/00379727-182-42322
56. Robert SD, Ismail AA, Wan Rosli WI. Trigonella foenum-graecum seeds lowers postprandial blood glucose in overweight and obese individuals. J Nutr Metab. 2014;2014:964873.
    PMID 25276421 · doi:10.1155/2014/964873 · PMC4167814
57. Robert SD, Ismail AA, Rosli WI. Reduction of postprandial blood glucose in healthy subjects by buns and flatbreads incorporated with fenugreek seed powder. Eur J Nutr. 2016;55(7):2275-80.
    PMID 26358163 · doi:10.1007/s00394-015-1037-4
58. Roberts KT. The potential of fenugreek (Trigonella foenum-graecum) as a functional food and nutraceutical and its effects on glycemia and lipidemia. J Med Food. 2011;14(12):1485-9.
    PMID 21861724 · doi:10.1089/jmf.2011.0002
59. Rouhi M, Hossieni MB, Khodaie L, Mohammad-Alizadeh-Charandabi S, Mirghafourvand M. Investigating the Effectiveness of Fenugreek on the Quantity of Breast Milk and the Level of Prolactin in Mothers of Preterm Newborns: A Randomized Controlled Clinical Trial. Curr Drug Res Rev. 2025;17(3):471-480.
    PMID 41239794 · doi:10.2174/0125899775313919240822102906
60. Sankhwar SN, Kumar P, Bagchi M, Rungta M, Bagchi D. Safety and Efficacy of Furosap®, a Patented Trigonella foenum-graecum Seed Extract, in Boosting Testosterone Level, Reproductive Health and Mood Alleviation in Male Volunteers. J Am Nutr Assoc. 2023;42(1):27-35.
    PMID 34694954 · doi:10.1080/07315724.2021.1978348
61. Sauvaire Y, Ribes G, Baccou JC, Loubatieères-Mariani MM. Implication of steroid saponins and sapogenins in the hypocholesterolemic effect of fenugreek. Lipids. 1991;26(3):191-7.
    PMID 2046485 · doi:10.1007/BF02543970
62. Sauvaire Y, Petit P, Broca C, Manteghetti M, Baissac Y, Fernandez-Alvarez J, et al.. 4-Hydroxyisoleucine: a novel amino acid potentiator of insulin secretion. Diabetes. 1998;47(2):206-10.
    PMID 9519714 · doi:10.2337/diab.47.2.206
63. Sewell AC, Mosandl A, Böhles H. False diagnosis of maple syrup urine disease owing to ingestion of herbal tea. N Engl J Med. 1999;341(10):769.
    PMID 10475807 · doi:10.1056/NEJM199909023411020
64. Shabil M, Bushi G, Bodige PK, Maradi PS, Patra BP, Padhi BK, et al.. Effect of Fenugreek on Hyperglycemia: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2023;59(2).
    PMID 36837450 · doi:10.3390/medicina59020248 · PMC9962665
65. Sharma RD, Raghuram TC, Rao NS. Effect of fenugreek seeds on blood glucose and serum lipids in type I diabetes. Eur J Clin Nutr. 1990;44(4):301-6.
    PMID 2194788
66. Sim TF, Hattingh HL, Sherriff J, Tee LB. The Use, Perceived Effectiveness and Safety of Herbal Galactagogues During Breastfeeding: A Qualitative Study. Int J Environ Res Public Health. 2015;12(9):11050-71.
    PMID 26371019 · doi:10.3390/ijerph120911050 · PMC4586661
67. Singh A, Gainder S, Banerjee P, Goel A, Kumar P, Mondal B, et al.. Efficacy of a Proprietary Fenugreek Seed Extract (Trigonella foenum-graecum, Furocyst®) in Women with Polycystic Ovary Syndrome (PCOS): a Randomized, Double-Blind, Placebo-Controlled Study. J Am Nutr Assoc. 2023;42(7):651-659.
    PMID 36219198 · doi:10.1080/27697061.2022.2126410
68. Smith SJ, Lopresti AL, Teo SYM, Fairchild TJ. Examining the Effects of Herbs on Testosterone Concentrations in Men: A Systematic Review. Adv Nutr. 2021;12(3):744-765.
    PMID 33150931 · doi:10.1093/advances/nmaa134 · PMC8166567
69. Srichamroen A, Thomson AB, Field CJ, Basu TK. In vitro intestinal glucose uptake is inhibited by galactomannan from Canadian fenugreek seed (Trigonella foenum graecum L) in genetically lean and obese rats. Nutr Res. 2009;29(1):49-54.
    PMID 19185777 · doi:10.1016/j.nutres.2008.11.002
70. Steels E, Rao A, Vitetta L. Physiological aspects of male libido enhanced by standardized Trigonella foenum-graecum extract and mineral formulation. Phytother Res. 2011;25(9):1294-300.
    PMID 21312304 · doi:10.1002/ptr.3360
71. Steels E, Steele ML, Harold M, Coulson S. Efficacy of a Proprietary Trigonella foenum-graecum L. De-Husked Seed Extract in Reducing Menopausal Symptoms in Otherwise Healthy Women: A Double-Blind, Randomized, Placebo-Controlled Study. Phytother Res. 2017;31(9):1316-1322.
    PMID 28707431 · doi:10.1002/ptr.5856
72. Swaroop A, Jaipuriar AS, Gupta SK, Bagchi M, Kumar P, Preuss HG, et al.. Efficacy of a Novel Fenugreek Seed Extract (Trigonella foenum-graecum, Furocyst) in Polycystic Ovary Syndrome (PCOS). Int J Med Sci. 2015;12(10):825-31.
    PMID 26516311 · doi:10.7150/ijms.13024 · PMC4615243
73. Turkyılmaz C, Onal E, Hirfanoglu IM, Turan O, Koç E, Ergenekon E, et al.. The effect of galactagogue herbal tea on breast milk production and short-term catch-up of birth weight in the first week of life. J Altern Complement Med. 2011;17(2):139-42.
    PMID 21261516 · doi:10.1089/acm.2010.0090
74. Uemura T, Hirai S, Mizoguchi N, Goto T, Lee JY, Taketani K, et al.. Diosgenin present in fenugreek improves glucose metabolism by promoting adipocyte differentiation and inhibiting inflammation in adipose tissues. Mol Nutr Food Res. 2010;54(11):1596-608.
    PMID 20540147 · doi:10.1002/mnfr.200900609
75. Vajdi M, Noshadi N, Bonyadian A, Golpour-Hamedani S, Alipour B, Pourteymour Fard Tabrizi F, et al.. Therapeutic effect of fenugreek supplementation on type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials. Heliyon. 2024;10(17):e36649.
    PMID 39286181 · doi:10.1016/j.heliyon.2024.e36649 · PMC11403534
76. Valette G, Sauvaire Y, Baccou JC, Ribes G. Hypocholesterolaemic effect of fenugreek seeds in dogs. Atherosclerosis. 1984;50(1):105-11.
    PMID 6696779 · doi:10.1016/0021-9150(84)90012-1
77. Verma N, Usman K, Patel N, Jain A, Dhakre S, Swaroop A, et al.. A multicenter clinical study to determine the efficacy of a novel fenugreek seed (Trigonella foenum-graecum) extract (Fenfuro™) in patients with type 2 diabetes. Food Nutr Res. 2016;60:32382.
    PMID 27733237 · doi:10.3402/fnr.v60.32382 · PMC5061863
78. Wankhede S, Mohan V, Thakurdesai P. Beneficial effects of fenugreek glycoside supplementation in male subjects during resistance training: A randomized controlled pilot study. J Sport Health Sci. 2016;5(2):176-182.
    PMID 30356905 · doi:10.1016/j.jshs.2014.09.005 · PMC6191980
79. Wankhede S, Mohan V, Thakurdesai P. Corrigendum to "Beneficial effects of fenugreek glycoside supplementation in male subjects during resistance training: A randomized controlled pilot study" [J Sport Health Sci 5 (2016) 176-182]. J Sport Health Sci. 2018;7(2):251.
    PMID 32099715 · doi:10.1016/j.jshs.2018.03.001 · PMC7033288
80. Wilborn C, Taylor L, Poole C, Foster C, Willoughby D, Kreider R. Effects of a purported aromatase and 5α-reductase inhibitor on hormone profiles in college-age men. Int J Sport Nutr Exerc Metab. 2010;20(6):457-65.
    PMID 21116018 · doi:10.1123/ijsnem.20.6.457
81. Younesy S, Amiraliakbari S, Esmaeili S, Alavimajd H, Nouraei S. Effects of fenugreek seed on the severity and systemic symptoms of dysmenorrhea. J Reprod Infertil. 2014;15(1):41-8.
    PMID 24695380 · PMC3955423
82. Zhou J, Chan L, Zhou S. Trigonelline: a plant alkaloid with therapeutic potential for diabetes and central nervous system disease. Curr Med Chem. 2012;19(21):3523-31.
    PMID 22680628 · doi:10.2174/092986712801323171
83. National Center for Biotechnology Information. PubChem Compound Summary for CID 11005, 4-Hydroxyisoleucine. Accessed 20 August 2026.
    Source
84. National Center for Biotechnology Information. PubChem Compound Summary for CID 5570, Sotolon. Accessed 20 August 2026.
    Source
85. National Center for Biotechnology Information. PubChem Compound Summary for CID 99474, Diosgenin. Accessed 20 August 2026.
    Source
86. National Library of Medicine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Fenugreek.
    Source
87. National Library of Medicine. Drugs and Lactation Database (LactMed). Fenugreek.
    Source

29 Evidence handling

Study type is named in the reporting sentence. Animal and cell findings identify a fraction, an isomer, or a metabolite; they are not used to imply a human outcome. Whole-seed powder, isolated fiber, hydro-alcoholic extract, and named proprietary saponin concentrates are not pooled in prose as if they were one exposure. Conflicting meta-analyses are left in conflict. Neelakantan et al., 2014 and Gong et al., 2016 are cited for the fasting-glucose reductions they reported. Shabil et al., 2023 is cited for the fasting-glucose null it reported. A newer null does not automatically supersede an older positive, and an older positive does not automatically survive a larger later review. Cochrane (Foong et al., 2020) is cited for the lactation question it asked, not as a dismissal of every first-week tea. LiverTox is cited as a regulator-grade hepatotoxicity statement, not as a primary trial.

References below were generated from NCBI records fetched for this build. Author lists, titles, journals, years, volumes and identifiers were read from those records. Recalled identifiers that resolved to unrelated papers, to other Trigonella species, to retracted records, or to a fermented Morinda product were discarded before drafting. Reeder and colleagues (Clinical Lactation, 2013) are named because secondary lactation writing cites them; the paper is not PubMed-indexed and is not given a PMID. Isolated 4-hydroxyisoleucine has no title-verified human randomized trial in this review; Chevassus et al., 2009 and 2010 remain extract studies. Sharma RD is cited as Sharma et al., 1990 (PMID 2194788); later Sharma nutrition-journal papers commonly recycled in reviews were not recovered as PMIDs in this hunt and are not cited.

Quantitative claims in the running text are traceable to the title-checked record. Extreme abstract percentages from industry-linked extract trials were not treated as load-bearing where PDF tables were not verified. Mixed-herb trials are attributed to the mixture. Commissioned plates were not used; figures are authored schematics and carry no third-party artwork. Project codes, scan counts, identity gates and rejection classes do not appear in the reader-facing text except as the source-library line on the masthead.